WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX) announced the first implantation of its Vercise DBS System as part of the INTREPID clinical trial.
The company commented that INTREPID is a prospective, multi-center, double-blinded, randomized, controlled study to evaluate the safety and effectiveness of motor function and overall quality of life in patients with the Vercise DBS System for the treatment of Parkinson's disease.
The Vercise DBS System is a neurostimulation device that delivers electrical signals to specific areas within the brain through individual lead contacts. It is the only system that allows physicians to adjust the current flow in fine increments based on patient needs, Boston Scientific noted.
Thd company stated that the first patient was implanted at Cedars-Sinai in Los Angeles by a team led by Michele Tagliati, M.D., director, Movement Disorders Program, and Adam Mamelak, M.D., FACS, FAANS, director, Functional Neurosurgery.
'The Vercise DBS System has the ability to deliver stimulation in a precise manner due to multiple independent current control which represents a significant opportunity for DBS therapy in the treatment of Parkinson's disease,' said Jerry Vitek, M.D., professor and chair, Department of Neurology, University of Minnesota and co-principal investigator of the trial.
Copyright RTT News/dpa-AFX
Jetzt für 0€ handeln - auf Smartbroker.de